11th Feb 2019 10:03
LONDON (Alliance News) - Life sciences company Optibiotix Health PLC said on Monday it has appointed EIWA Trading Co Ltd as the exclusive distributor for its LPLDL products in Japan.
In particular, EIWA has exclusive rights to import, market and distribute OptiBiotix's probiotic strain lactobacillus plantarum LPLDL, which reduces cholesterol and blood pressure for a three year-period.
EIWA will be able to market LPLDL as a food and dairy ingredient as well as a food supplement in the country.
The market exclusivity is linked to increasing minimum annual volumes to maximise the financial return for both Optibiotix and EIWA.
"We are pleased to announce this distribution agreement with EIWA. This deal provides OptiBiotix market access in Japan, the main national market for probiotics within the largest region for probiotics in the world. We have chosen EIWA as they are a well-known and respected provider of probiotics to the Japanese food, dairy and supplement industries, creating the potential to extend the use of LPLDL beyond supplements in a major international market," said Chief Executive Officer Stephen O'Hara.
Shares in OptiBiotix Health were up 4.0% at 86.80 pence on Monday.
Related Shares:
OptiBiotix Health